We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Scantek and Medilead in Distribution Alliance

By MedImaging staff writers
Posted on 07 Sep 2005
Scantek Medical, Inc. More...
(Cedar Knolls, NJ, USA) has entered into a distribution agreement with Medilead in which Scantek granted Medilead (Ljubljana, Slovenia) an exclusive, perpetual license to distribute the BreastCare/BreastAlert differential temperature sensor device in Bosnia-Herzegovina, Bulgaria, Croatia, Macedonia, Montenegro, Serbia, and Slovenia.

Medilead is a medical sales company based in Central Europe. Scantek is a high-tech medical company engaged in developing, manufacturing, selling, and licensing of products and devices to assist in the early detection and diagnosis of disease. Initially, Scantek intends to focus upon manufacturing, selling, and licensing the BreastCare device. The BreastCare device is to be used by clinicians as an adjunct to clinical breast examination, mammography, and other established techniques for the detection of breast disease.

This system can considerably improve early detection of breast cancer when used as an adjunct to clinical breast examination and mammography. In clinical studies in the United States (i.e., Memorial Sloan Kettering Cancer Center [NY, NY, USA], MD Anderson Cancer Center [Houston, TX, USA], the University of California, Los Angeles [USA], as well as and the European Institute of Oncology [Milan, Italy]), the BreastCare system has been clinically proven capable of recognizing metabolic activity (angiogenesis) by recording the heat differentiation of corresponding areas of the breast. At the present time, in developing countries, as well as industrial nations, there is no available screening procedure which identifies increased metabolic activity due to abnormal cell proliferation.





Related Links:
Scantek Medical
Medilead

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Pediatric Mask
Respire SOFT
Hypodermic Syringe
SurTract™ Safety Syringe
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.